Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRS CK STORM in Acute Respiratory Infection With Cytokine Storm
NCT06684379Phase 2Recruiting
- Sponsor
- Peaches Biotech
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PRS CK STORM in Systemic Inflammatory Response Syndrome (SIRS) and Acute Respiratory Infection (ARI) (3 arms), sponsored by Peaches Biotech. Primary endpoints: Adverse Events up to 12 months, Serious Adverse Events up to 12 months and 1 more. Started Oct 2024; status: recruiting.
02
Drugs
PRS CK STORM
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)Acute Respiratory Infection (ARI)
Beyond the preview
Go deeper on NCT06684379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06684379.